GLP-1 monotherapy
Semaglutide
STEP-1: ~15% mean body-weight reduction at 68 weeks.
- Once-weekly subcutaneous injection
- Compounded for cost + access during shortages
- Provider-supervised dosing; refills require a fresh check-in
Our mission
A real GLP-1 practice for the patient who's already tried everything else.
Rx-Dr exists for the patient who's been told just eat less for fifteen years. Primary care said maybe next year. Insurance denied the prior-auth. By the time they reach our intake, they already know more about GLP-1 protocols than most front-desk schedulers.
Weight is not a willpower diagnosis. The medication for it is one of the most-studied drug classes in modern medicine. Access shouldn't take nine phone calls.
Three principles, on the wall
- 01The patient is not the product.
No upsell at checkout. No retargeting flow that preys on month-four discouragement. No data handed to a third-party broker.
- 02The medicine is the answer the body needs — not the answer the storefront wants.
Our providers can decline, pause, or switch you. They get paid the same either way.
- 03The boring middle is the whole job.
Most weight-loss companies optimize the first sale. We optimize the eighth refill — the one where the protocol either holds or doesn't.
Things we don't do
The clearer way to describe a focused practice is by what gets cut.
- 01Up-sell you peptides at checkout.
If we don't prescribe it ourselves, we don't list it.
- 02Run AI as the first reviewer.
A clinician licensed in your state reads your intake. Software just assembles the chart.
- 03Keep the price hidden until checkout.
Per-month price is on the product page. No consult fee. No activation. No surprises.
- 04Ghost you on month four.
The same provider who started you titrates you through the plateau.
- 05Pretend insurance pays.
Compounded GLP-1s aren't covered. We don't waste your two weeks finding that out.
Operationally
What happens after you hit submit.
Times are typical, not promises.
- T + 0
Intake submitted.
Pre-screened automatically for state + contraindications.
- T + 1–24h
Provider review.
A clinician licensed in your state reads the chart. Approve, request info, or decline.
- T + 24–48h
Prescription written.
E-Rx routes to the partner pharmacy with the audit trail attached.
- T + 3–6 days
Medication shipped.
Cold-chain packaging from a 503A pharmacy. Lowest titration dose first.
- Month 1+
Ongoing review.
Same provider escalates, pauses, or switches you. Every refill is reviewed.
The catalog
Two molecules. Not a third — yet.
We add to the catalog when our providers want to prescribe the next entrant for a family member.
GLP-1 + GIP dual-agonist
Tirzepatide
SURMOUNT-1: ~21% mean body-weight reduction at 72 weeks.
- Once-weekly subcutaneous injection
- Dual-incretin mechanism — stronger trial outcomes
- Provider-supervised dosing; refills require a fresh check-in
We built the practice we wanted to staff — not the funnel a marketing team would draw.
— Working principle. Posted above every provider's editor.
Receipts
The boring stuff, in order.
- HIPAA
- PHI encrypted at rest (AES-256) and in transit (TLS 1.3). Audit logs retained per §164.312.
- LegitScript
- Annually re-audited as a verified telehealth practice. Our certification number is on the footer.
- FDA-Registered 503A
- Partner pharmacy operates under federal compounding rules. Every batch carries a traceable lot record.